Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

U.S. FDA approves Bristol Myers' bowel disease treatment

Published 05/27/2021, 05:36 PM
Updated 05/27/2021, 05:40 PM
© Reuters. FILE PHOTO: A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder

Bristol Myers (NYSE:BMY) Squibb said on Thursday the U.S. Food and Drug Administration approved its oral drug Zeposia to treat adults with ulcerative colitis, a chronic inflammatory bowel disease.

Bristol Myers gained the drug, approved last year for treating multiple sclerosis patients, in 2019 through its $74 billion buyout of Celgene (NASDAQ:CELG).

Zeposia last year June met the main goals of a late-stage study, showing patients who took it achieved clinical remission of ulcerative colitis when compared to placebo. (https://reut.rs/2SA6RFe)

Cowen analyst Steve Scala, in a note on May 23, estimated Zeposia sales of $150 million in 2021, $400 million in 2022 and $1 billion in 2025.

© Reuters. FILE PHOTO: A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder

Zeposia will compete with Takeda Pharmaceutical Co's drug Entyvio, which was approved in 2014 by the FDA for ulcerative colitis.

The European Medicines Agency is currently reviewing the marketing application for Zeposia to treat ulcerative colitis. A decision from the agency is expected in the second half of 2021, Bristol Myers said.

Latest comments

The global market for ulcerative colitis drugs anticipated to reach $12 billion by 2027, growing steadily at a CAGR of 6.0% over the forecast period, mostly driven by the increasing prevalence of ulcerative colitis, and introduction of several new therapies, mainly the IL-23 and JAK inhibitors in the recent years. https://www.ihealthcareanalyst.com/global-ulcerative-colitis-drugs-market/  The global market for Crohn’s disease therapeutics expected to reach $13.5 billion by 2027, expanding at a CAGR of 6.1% over the forecast period, driven by novel biologic drugs, and its widely prescribed status due to its efficacy, safety and faster mode of action for wide range of patients. https://www.ihealthcareanalyst.com/global-crohns-disease-therapeutics-market/
My husband was diagnosed with MULTIPLE SCLEROSIS five years ago. It’s very difficult for me to get him on board with major changes to his diet. We eat organic, non-GMO at home but his mom constantly gives us donuts, bagels, etc. I feel so lucky and happy i found World Herbs clinic on the internet. My husband only used their MS HERBAL FORMULA for three months and He was fully recovered. I believe this will be of great help to all MS patients across the world. World Herbs clinic MS formula will reverse your condition, So go for it.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.